Sosei Co., Ltd., HRA, And Sandoz/Hexal Australia To Conclude Sublicensing Agreement For "Morning After Pill" SOH-075

Tokyo (JCN) Dec 21, 2005 - Japanese biopharmaceutical company Sosei has announced that it and French pharmaceutical Laboratoire HRA Pharma (HRA) have entered into a sublicensing agreement with Sandoz/Hexal Australia, a wholly owned subsidiary of Novartis AG, for the distribution of SOH-075, an oral levonorgestrel emergency contraceptive developed by HRA. Under the agreement terms, Sandoz Hexal will be licensed to distribute SOH-075 in Australia. Orally administered within 72 hours after an unprotected sexual intercourse, the drug can prevent pregnancy.